1. Home
  2. MGX

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).

Founded: 2018 Country:
United States
United States
Employees: N/A City: EMERYVILLE
Market Cap: 268.6M IPO Year: 2024
Target Price: $17.83 AVG Volume (30 days): 121.8K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.91 EPS Growth: N/A
52 Week Low/High: $5.50 - $12.74 Next Earning Date: 05-14-2024
Revenue: $47,258,000 Revenue Growth: N/A
Revenue Growth (this year): -33.65% Revenue Growth (next year): 9.61%

Share on Social Networks:

Stock Insider Trading Activity of METAGENOMI INC (MGX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Novo Holdings A/S MGX 10% Owner Feb 9 '24 Buy $10.25 100,000 $1,025,000.00 100,000 SEC Form 4
Novo Holdings A/S MGX 10% Owner Feb 9 '24 Buy $15.00 800,000 $12,000,000.00 1,739,175 SEC Form 4